Protelos® evAluation iN THe osteoporotic mEn and wOmen under daily practice conditioNs

ISRCTN ISRCTN73451388
DOI https://doi.org/10.1186/ISRCTN73451388
Secondary identifying numbers IC4-12911-102-DEU
Submission date
10/10/2012
Registration date
27/11/2012
Last edited
22/01/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims:
Osteoporosis affects postmenopausal women and elderly men, and causes loss of bone mass and damage to the bone structure. This leads to an increased risk of fractures. Death after such fractures is more likely. Protelos® is a medicine, which was shown to reduce fracture rates in postmenopausal women. Currently it has been approved for treatment of osteoporosis in men. In study we aim to observe the treatment of osteoporosis with Protelos® in men and postmenopausal women, and see if this has an effect in regards to pain reduction and quality of life.

Who can participate?
Men and postmenopausal women with osteoporosis who have an increased risk of fractures.

What does the study involve?
All patients involved in the study will be treated with Protelos®. The participants will be asked to attend a follow up visit after 3 months. During this visit, a routine investigation will be carried out where information on osteoporosis, other diseases the participant may have and other medications they are taking and pain will be completed. The participants will also be asked to fill out a quality of life questionnaire at each visit.

What are the possible benefits and risks of participating?
The patients have no particular benefits or risks of participating in this study. The treatment given to the participants is part of their daily routine and free to withdraw from the study at any time without giving a particular reason.

Where is the study run from?
The study will be carried out by orthopedic surgeons across Germany.

When is the study starting and how long is it expected to run for?
The study started in October 2012 and is due to end in May 2013. Participants will be recruited until February 2013.

Who is funding the study?
Servier Deutschland, GmbH.

Who is the main contact?
Dr Peter Martinka
peter.martinka@de.netgrs.com

Contact information

Prof Johann Diederich Ringe
Scientific

Westdeutsches Osteoporose-Zentrum
Klinikum Leverkusen gGmbH
Dhünnberg 60
Leverkusen
51375
Germany

Email ringe@klinikum-lev.de

Study information

Study designObservational prospective multicentre open-label study
Primary study designObservational
Secondary study designNon-randomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleProtelos® evaluation in the osteoporotic men and women under daily practice conditions. A multicentric prospective observational study
Study acronymPANTHEON
Study objectivesEffects of therapy with Protelos® (Strontium ranelate) on the pain perception and quality of life in men and postmenopausal women with osteoporosis under daily routine in an observational prospective multicentre trial carried out by orthopedic surgeons and general practitioners.
Ethics approval(s)Freiburg Ethics Commission International (FEKI), 10/09/2012
Health condition(s) or problem(s) studiedOsteoporosis
InterventionObservational study to get information about therapy of osteoporosis with Protelos®; under daily routine practice by orthopedic surgeons and general practitioners.

The treatment decision must be made prior to study initiation. Treating physicians will confirm the diagnosis of osteoporosis at baseline. After the baseline visit, there is a final visit after approx. 3 months.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Protelos® (Strontium ranelate)
Primary outcome measure1. Effects of Protelos® on the osteoporosis-related pain
2. Effects of Protelos® on quality of life assessed by EQ-5D
3. Effects of Protelos® on analgesics prescription
4. Information about how Protelos® SmPC and patient information are followed via standardised documentation
5. Analysis of general tolerability of Protelos® under routine conditions via standardised adverse reactions documentation and standardised documentation of therapy discontinuation
6. Analysis of unknown adverse drug reactions via standardised documentation
Secondary outcome measuresNo secondary outcome measures
Overall study start date08/09/2012
Completion date31/05/2013

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants2960
Key inclusion criteria1. Adult men with osteoporosis at increased risk of fractures
2. Postmenopausal women with osteoporosis at increased risk of fractures
Key exclusion criteria1. Does not meet inclusion criteria
2. In addition, doctors involved in the trial should follow the Summary of Product Characteristics (SmPC) for Protelos®, which includes the following contraindications:
2.1 Hypersensitivity to the active substance or to any of the excipients.
2.2 Current or previous venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism.
2.3 Temporary or permanent immobilisation due to e.g. post-surgical recovery or prolonged bed rest.
Date of first enrolment08/09/2012
Date of final enrolment01/02/2013

Locations

Countries of recruitment

  • Germany

Study participating centre

Westdeutsches Osteoporose-Zentrum
Leverkusen
51375
Germany

Sponsor information

Servier Deutschland GmbH (Germany)
Industry

c/o Dr. Peter Martinka
Medical Affairs Officer
Elsenheimerstraße 53
München
80687
Germany

Phone +49 (0)89 5709501
Email peter.martinka@de.netgrs.com
Website http://www.servier.de
ROR logo "ROR" https://ror.org/05wk4ae67

Funders

Funder type

Industry

Servier Deutschland GmbH (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Abstract results results presented at DGRh 17/09/2014 No No

Editorial Notes

22/01/2019: Publication reference added.